GlassScriptPhysician profile
Ariel Medina
NPI 1073561056
$5,234.21
in general payments reported to CMS, 2019-2025
28 companies · $799 in 2025
The $799 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $961 · 2020: $725 · 2021: $928 · 2022: $505 · 2023: $631 · 2024: $687 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,109 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,109.37 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,069.62 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $689.70 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $436.80 | 2019-2024 | Trulance |
| Amgen INC. | $427.16 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $400.94 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $362.21 | 2019-2025 | Ozempic, Rybelsus |
| Ironwood Pharmaceuticals, INC | $328.19 | 2020-2025 | Linzess |
| Abbvie INC. | $259.89 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $259.76 | 2019-2022 | |
| Allergan, INC. | $187.49 | 2019 | |
| Novartis Pharmaceuticals Corporation | $134.33 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $131.97 | 2021-2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.42 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $69.79 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Dexcom, INC. | $60.67 | 2021-2024 | Dexcom G6 Transmitter |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $48.29 | 2019 | |
| Exact Sciences Corporation | $36.87 | 2024 | Cologuard Collection Kit |
| Shockwave Medical, INC | $34.12 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Otsuka America Pharmaceutical, INC. | $30.68 | 2023 | Rexulti |
| Endo Pharmaceuticals INC. | $19.37 | 2022 | |
| Alexion Pharmaceuticals, INC. | $17.04 | 2021 | |
| Ardelyx, INC. | $16.58 | 2025 | Ibsrela |
| Redhill Biopharma INC. | $16.13 | 2021 | |
| Abbott Laboratories | $15.97 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.55 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.36 | 2022 | |
| Amarin Pharma, INC. | $12.46 | 2019 | |
| Eisai INC. | $11.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ariel Medina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.